Novartis Willing To “Walk Away” From Chiron Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.